Association Between Thrombolytic Door-to-Needle Time and 1-Year Mortality and Readmission in Patients With Acute Ischemic Stroke.

dc.contributor.author

Man, Shumei

dc.contributor.author

Xian, Ying

dc.contributor.author

Holmes, DaJuanicia N

dc.contributor.author

Matsouaka, Roland A

dc.contributor.author

Saver, Jeffrey L

dc.contributor.author

Smith, Eric E

dc.contributor.author

Bhatt, Deepak L

dc.contributor.author

Schwamm, Lee H

dc.contributor.author

Fonarow, Gregg C

dc.date.accessioned

2020-12-04T19:35:52Z

dc.date.available

2020-12-04T19:35:52Z

dc.date.issued

2020-06

dc.date.updated

2020-12-04T19:35:51Z

dc.description.abstract

Importance:Earlier administration of intravenous tissue plasminogen activator (tPA) in acute ischemic stroke is associated with reduced mortality by the time of hospital discharge and better functional outcomes at 3 months. However, it remains unclear whether shorter door-to-needle times translate into better long-term outcomes. Objective:To examine whether shorter door-to-needle times with intravenous tPA for acute ischemic stroke are associated with improved long-term outcomes. Design, Setting, and Participants:This retrospective cohort study included Medicare beneficiaries aged 65 years or older who were treated for acute ischemic stroke with intravenous tPA within 4.5 hours from the time they were last known to be well at Get With The Guidelines-Stroke participating hospitals between January 1, 2006, and December 31, 2016, with 1-year follow-up through December 31, 2017. Exposures:Door-to-needle times for intravenous tPA. Main Outcomes and Measures:The primary outcomes were 1-year all-cause mortality, all-cause readmission, and the composite of all-cause mortality or readmission. Results:Among the 61 426 patients treated with tPA within 4.5 hours, the median age was 80 years and 43.5% were male. The median door-to-needle time was 65 minutes (interquartile range, 49-88 minutes). The 48 666 patients (79.2%) who were treated with tPA and had door-to-needle times of longer than 45 minutes, compared with those treated within 45 minutes, had significantly higher all-cause mortality (35.0% vs 30.8%, respectively; adjusted HR, 1.13 [95% CI, 1.09-1.18]), higher all-cause readmission (40.8% vs 38.4%; adjusted HR, 1.08 [95% CI, 1.05-1.12]), and higher all-cause mortality or readmission (56.0% vs 52.1%; adjusted HR, 1.09 [95% CI, 1.06-1.12]). The 34 367 patients (55.9%) who were treated with tPA and had door-to-needle times of longer than 60 minutes, compared with those treated within 60 minutes, had significantly higher all-cause mortality (35.8% vs 32.1%, respectively; adjusted hazard ratio [HR], 1.11 [95% CI, 1.07-1.14]), higher all-cause readmission (41.3% vs 39.1%; adjusted HR, 1.07 [95% CI, 1.04-1.10]), and higher all-cause mortality or readmission (56.8% vs 53.1%; adjusted HR, 1.08 [95% CI, 1.05-1.10]). Every 15-minute increase in door-to-needle times was significantly associated with higher all-cause mortality (adjusted HR, 1.04 [95% CI, 1.02-1.05]) within 90 minutes after hospital arrival, but not after 90 minutes (adjusted HR, 1.01 [95% CI, 0.99-1.03]), higher all-cause readmission (adjusted HR, 1.02; 95% CI, 1.01-1.03), and higher all-cause mortality or readmission (adjusted HR, 1.02 [95% CI, 1.01-1.03]). Conclusions and Relevance:Among patients aged 65 years or older with acute ischemic stroke who were treated with tissue plasminogen activator, shorter door-to-needle times were associated with lower all-cause mortality and lower all-cause readmission at 1 year. These findings support efforts to shorten time to thrombolytic therapy.

dc.identifier

2766633

dc.identifier.issn

0098-7484

dc.identifier.issn

1538-3598

dc.identifier.uri

https://hdl.handle.net/10161/21835

dc.language

eng

dc.publisher

American Medical Association (AMA)

dc.relation.ispartof

JAMA

dc.relation.isversionof

10.1001/jama.2020.5697

dc.subject

Humans

dc.subject

Brain Ischemia

dc.subject

Tissue Plasminogen Activator

dc.subject

Fibrinolytic Agents

dc.subject

Thrombolytic Therapy

dc.subject

Patient Readmission

dc.subject

Infusions, Intravenous

dc.subject

Incidence

dc.subject

Cause of Death

dc.subject

Proportional Hazards Models

dc.subject

Retrospective Studies

dc.subject

Follow-Up Studies

dc.subject

Aged

dc.subject

Aged, 80 and over

dc.subject

Female

dc.subject

Male

dc.subject

Stroke

dc.subject

Time-to-Treatment

dc.title

Association Between Thrombolytic Door-to-Needle Time and 1-Year Mortality and Readmission in Patients With Acute Ischemic Stroke.

dc.type

Journal article

duke.contributor.orcid

Xian, Ying|0000-0002-1237-1162

duke.contributor.orcid

Matsouaka, Roland A|0000-0002-0271-5400

pubs.begin-page

2170

pubs.end-page

2184

pubs.issue

21

pubs.organisational-group

School of Medicine

pubs.organisational-group

Duke Clinical Research Institute

pubs.organisational-group

Neurology, Neurocritical Care

pubs.organisational-group

Medicine, Clinical Pharmacology

pubs.organisational-group

Duke

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Neurology

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Medicine

pubs.organisational-group

Biostatistics & Bioinformatics

pubs.organisational-group

Basic Science Departments

pubs.publication-status

Published

pubs.volume

323

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Man-2020-Association Between Thrombolytic Door.pdf
Size:
556.39 KB
Format:
Adobe Portable Document Format